Arbutus Biopharma, Vaccitech Team Up To Develop Combo Treatment For Hepatitis B

  • Arbutus Biopharma Corporation ABUS and Vaccitech plc VACC have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy.
  • The Phase 2a trial will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of Arbutus's AB-729, followed by Vaccitech's VTP-300, in NrtI-suppressed subjects.
  • The trial will start in the second half of 2021 and will be managed by Arbutus, subject to oversight by a joint development committee comprised of Arbutus and Vaccitech. 
  • The parties retain full rights to their respective product candidates and split all costs associated with the clinical trial. 
  • Under the agreement, the parties intend to undertake a larger Phase 2b clinical trial depending on the initial Phase 2a clinical trial results.
  • AB-729 is an RNA interference (RNAi) therapeutic targeted to hepatocytes.
  • VTP-300 utilizes Vaccitech's ChAdOx1-HBV/MVA-HBV prime-boost combination to elicit an immune response against HBV. 
  • Price Action: ABUS shares are down 1.86% at $2.89, while VACC shares are up 1.34% at $15.15 on the last check Tuesday.

Posted In: BriefsHepatits BBiotechNewsPenny StocksHealth CareContractsSmall CapGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.